Thrilled to announce our Annual Meeting Featured Voices! Get ready for a wealth of expert perspectives and engaging discussions throughout the meeting. Don't miss out – follow along and contribute to the conversation using the official hashtag: #ASCO25

Hot off the press in @ascocancer.bsky.social journal JCO Oncology Advances: Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches ascopubs.org/doi/10.1200/... from our University of Minnesota group led by Dr. Ajay Prakash - #Immunoonc #immunotherapy

HER2 in NSCLC is underrecognized & complex. Grateful to join @cor2edmeded.bsky.social with an expert path colleague to discuss timely testing and clinical utility—now targetable on/off clinical trials. Thanks @oncbrothers.bsky.social for the invite! #lcsm #oncMedEd cor2ed.com/lung-connect...

#Cabozantinib is now approved in #NET based off #CABINET study! We discussed the design, findings, sequencing, and AEs with Dr. Aman Chauhan (full discussion and one page takeaway 👇👇) Full 🗣️: ⭐️ Oncbrothers.com/cabinet ⭐️ Also on the “Oncology Brothers” podcast #OncSky #MedSky #GiOnc

I recently had the privilege of joining the @oncbrothers.bsky.social to discuss all things #PancreaticCancer, including current and emerging treatment options that are bringing hope for better outcomes for patients. Many thanks👊 oncbrothers.com/pancreatic-a... www.cancernetwork.com/treatment-al...

Less than 2 months to #ASCO25! Join us to discuss the current SoC➕how the data from #ASCO25 will change/reinforce our practice! ⭐️ InPerson: May 31st, 2025 ⭐️ Location📍Marriott Marquis ⭐️ Time: 6:30-9:00PM ⭐️ Register bit.ly/aioasco25 #AdvInOnc25 #OncSky

#Zolbetuximab was approved based off #GLOW & #SPOTLIGHT (one page/slide summary attached)! We discussed the design, findings, sequencing and AEs/management w/ #KoheiShitara Full Discussion: ⭐️ Oncbrothers.com/zolbetuximab... ⭐️ Also on the “Oncology Brothers” podcast #gism #CanSky #OncSky

Treatment Algorithm series: discussion on HER2+ #BreastCancer ✅ APT data/TCHP ✅ Metastatic disease ✅ Her2/ER/PR+ Full discussion: ⭐️ oncbrothers.com/her2positive... ⭐️ www.cancernetwork.com/treatment-al... ⭐️ “Oncology Brothers” podcast #bcsm #CancerSky #OncSky @drsarahsammons.bsky.social

What is Dr. Brian Betts most excited about for #TANDEM25? 🥁 Learn more about Roswell Park's involvement: www.roswellpark.org/newsroom/202...

Publication by @ascocancer.bsky.social on academic medical oncology. Makes me wonder- how do we encourage more transparency among institutions to set these standards ? ascopubs.org/doi/10.1200/...

As @asco #GU25 approaches worth considering again the true value of Progression Free Survival (#PFS) endpoints in #ProstateCancer www.nature.com/articles/s41...

Treatment Algorithm series: starting off w/ TNBC discussion @vkaklamani.bsky.social ✅ Early disease ✅ ≥T2 or N+ disease ✅ Metastatic disease ✅ Low ER/PR+ Full 🗣️: ⭐️ oncbrothers.com/how-to-treat... ⭐️ www.cancernetwork.com/treatment-al... ⭐️ “Oncology Brothers” podcast #bcsm #BreastCancer

The #GU25 abstracts are now available! Late-Breaking Abstracts (LBAs) will be released at 7:00 AM PT on their day of presentation. Check out the latest practice-changing science in GU cancers here: brnw.ch/21wQBxm Co-sponsored by @astro-org.bsky.social and Society of Urologic Oncology

🚨In <1 wk, it’s #GU25🚨 Let’s discuss the current SoC ➕ how the data will change/reinforce our practice at #AdvInOnc25: - Bladder Ca - Prostate Ca - RCC *Join us LIVE* 📅 Date: Feb 12, 2025 ⏰ Time: 6:00-8:00PM 📝 bit.ly/guaio25 #OncSky #MedSky #gusm #Oncology #Cancer #CanSky

AMPLIFY for 1L CLL now in @nejm.org 🔑 takeaways: 1️⃣ Fixed-duration #acalabrutinib + #venetoclax (±obinutuzumab) improved PFS (3-year): 76% (A+V), 83% (AVO) vs 66% (Chem) 2️⃣ AVO showed deeper responses but higher infection risk 3️⃣ New SoC for many #OncSky #CanSky #HemeSky

Recognizing the brilliant #WomenInMedicine today 2/3/25 who continue to persevere, break glass ceilings and improve healthcare #NWPD25 #IamBlackwell @quirogad.bsky.social @aryaroy.bsky.social @nerealliamd.bsky.social @drsgraff.bsky.social @drsarahsammons.bsky.social @maryamlustberg.bsky.social

Nice discussion on management of intermediate risk #HCC hosted by @oncbrothers.bsky.social! Cc: @markyarchoan.bsky.social #liversky #oncsky oncbrothers.com/liver-2024-4

T-DXd approved today after progression on CDK4/6 inhibitor for HR+ HER2-low and HER2-ultralow metastatic breast cancer based on results of DESTINY-Breast06. #bcsm #oncsky

T-Dxd approved as first line chemo in HR+, HER2 low or ultra low disease. Do all patients need it first line? Probably not. But great option for higher risk. #bcsm #oncosky

🔥🔥🔥BREAKWATER🔥🔥🔥 BRAF V600E mut #CRC SOC (FOLFOX) +/- encorafenib + cetuximab EC + FOLFOX shows: ✅⬆️ORR ✅Strong suggestion of ⬆️OS 🚨EC + FOLFOX is a new SOC‼️ Pub available: idp.nature.com/authorize?re... #GI25 @ascocancer.bsky.social

#GI25 highlights #CommunityOnc: 1. #SCIENCE: Adv Eso SCC 2. #ESOPEC publication (Eso/GEJ/Ga) 3. Chemo in resectable Panc Ca 4. #StarterNET: GEP-NET 5. #CM8HW: dMMR/MSI-H mCRC 6. #BREAKWATER: BRAFV600E mCRC 7. ctDNA: #BESPOKE + SWOG80702 #OncSky #gism @ascocancer.bsky.social 1/8

Join us for Intersections: Personalized Risk Assessment for Gastrointestinal Cancers with Mary Uan-Sian Feng, MD. Gain insights on risk scores, biomarkers for screening, and more cutting-edge updates at #GI25!

So much excited data shared on Day 1️⃣ of #GI25 from #biomarker 🎯 testing in #esocsm #stcsm to the role of #RT in #esocsm in light 💡 of #ESOPEC. Excited for more great science and discovery on Day 2️⃣!

Datopotamab deruxtecan now #FDA approved off #TROPIONBreast01: #DatoDXd Vs Chemo post 1-2L HR+ mBC - ⏰ to 1st Rx: 8.2 vs 5mos (favoring Dato) - ⬆️ PFS 6.9mos vs 4.5 mos - Better AE + QoL favoring DatoDXd - AEs: Fatigue, infusion reactions, stomatitis #bcsm #OncSky #MedSky

5/20 #TumorBoardTuesday 👩‍⚕️Mini Tutorial 2👩‍⚕️ Pt characteristics in INAVO120: No prior treatment for ABC PIK3CA mut a1c≤6.0, fasting BG<126 ~Half with ≥3 involved organ sites ~Half with liver involvement, ~40% with 🫁 involvement ~1/3 with 1° endocrine resistance, 2/3 with 2° @dr-rshatsky.bsky.social

Who has tried to add Palbo to maintenance let + HP? Know it isn't "approved yet", but wasn't successful. Anyone been successful for coverage yet with #PATINA? @ptarantinomd.bsky.social @hoperugo.bsky.social @stolaney1.bsky.social @vkaklamani.bsky.social @jochien.bsky.social

Hello all, wanted to let you know about a fantastic interactive learning opportunity! This Tuesday the 14th my lovely fellow and I will be presenting Tumor board Tuesday #TBT about new developments in HR+ MBC! It will be 5pm pacific, 8pm eastern! #bcsm #OncSky #CanSky #MedSky #breastcancer #MBC

#GISeries: #Zanidatamab was recently approved based off #HerizonBTC01! We 🗣️ design, findings, sequencing and AEs/management with Dr. Shubham Pant Full Discussion: - Oncbrothers.com/zanidatamab-... - Also on the “Oncology Brothers” podcast #OncSky #MedSky #gism #GI25

Adjuvant IO trials in muscle-invasive urothelial carcinoma: IMvigor010: Atezo DFS HR 0.89, OS HR 0.85. CheckMate 274: Nivo DFS HR 0.71, OS HR 0.76. AMBASSADOR: Pembro DFS HR 0.73, OS HR 0.98. #oncology #cancer @oncoalert.bsky.social @oncbrothers.bsky.social @erplimackmd.bsky.social @nejm.org

Early-onset colorectal cancer (<50 yrs) is rising, linked to factors like Western diets, obesity, and gut microbiota changes. Prevention & early detection strategies are vital. #ColorectalCancer #Oncology #CancerPrevention @oncoalert.bsky.social @oncbrothers.bsky.social rdcu.be/d49OZ

2024 was an exciting year for #lungcancer advances! As we mark the 20th anniversary of the discovery of EGFR's role in NSCLC, we celebrate this era of #precisionmedicine that is extending and improving patients' lives. #LCSM

2024 approvals: Summary of 14 new drugs/indications in #LungCancer by FDA 1. #Tepotinib 2. #Osimertinib x2 3. #Alectinib 4. #Tarlatamab 5. #Zenocutuzumab 6. #Durvalumab x2 7. #Amivantamab x2 8. #Nivolumab (now SubQ) 9. #Ensartinib #lcsm #OncSky #MedSky #Cancer

2024 approvals: Summary of 12 new 💊indications in heme malignancies by FDA: 1. #Zanubrutinib 2. #Ponatinib 3. #LisoCel x2 4. #Imetelstat 5. #Epcortimab 6. #Daratumuab 7. #Axatilimab 8. #Isatuximab 9. #Asciminib 10. #ObiCel 11. #Revumenib #HemeSky #OncSky #mmsm #leusm #MedSky #lymsm

My Annual Updated Myeloma Treatment Algorithms thread. Bookmark! #ASH24 #ASH24VR 1. Newly diagnosed transplant ineligible. Quadruplet unless frail. Maintenance varies by risk stratification.

#Encorafenib + #Ceruximab + mFOLFOX is approved in 1L for BRAFV600e based off #BREAKWATER - ORR 61% vs 40% - mDoR: 13.9mos vs 11.1mos - AEs:GI tox, rash #cansky #oncsky #gism

game-changer for tailoring treatment in high-risk cases. #Oncology #ProstateCancer @oncoalert.bsky.social @oncbrothers.bsky.social @apccc.bsky.social

🚨In 5 weeks it’s #GI25🚨 Let’s discuss the current SoC and how the new data will change/reinforce our practice at #AdvInOnc25: - Upper GI - CRC - HepatoPanc & NET **Join us LIVE** 📅 **Date**: Jan 24, 2025 ⏰ **Time**: 6:00-8:00PM Register here: bit.ly/aiogi25 #OncSky #CanSky #MedSky #GISM

Just Out FDA 🇺🇸 approved ensartinib for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer ( #NSCLC ) 🫁who have not received prior ALK-targeted therapy. https://buff.ly/4gicU7q

Another ALK inhibitor (#ensartinib) gets FDA approval eXalt3 study: - 1L, Ph III, ALK+ mNSCLC vs Crizotinib - Ensartinib vs crizotinib (NR vs 12.7mos, HR: 0.45) - CNS ORR 64% w/ ensartinib vs 21% - AES: rash, 💪 pain, nausea #OncSky #MedSky #lcsm #CanSky

#GISeries: #Hepatocellular Ca 2/4: 2nd Line Treatment and when to switch! 🌟IO, TKIs, #supponc in 2L 🌟AEs/Management Full 🗣️ - Oncbrothers.com/hcc-advanced... - cor2ed.com/hcc-connect/... - Also on “Oncology Brothers” podcast #OncSky #MedSky #gism @arndtvogel.bsky.social

#HearHer in Brazil thanks to @paulobergerot.bsky.social and @crisbergerot.bsky.social Obrigada!

#SABCS24 Day 3 Highlights #CommunityOnc: 1. #EUROPA: ET vs XRT HR+ ≥70 yrs 2. #PATINA: CDK4/6 HR+ HER2+ new SoC 3. #COMET: DCIS 4. #SUPREMO: XRT post mastectomy 5. #INSEMA: ALNBx @sabcs.bsky.social @theaacr.bsky.social @drsarahsammons.bsky.social @erikahamilton9.bsky.social

Great real world case discussion including #OSU @stoverlab.bsky.social @osuwexmed.bsky.social on the use of liquid biopsies in #mBC treatment decisions @sabcs.bsky.social #SABCS24 #bcsm Take Away - not ready for broad use in all pts, but may help in specific cases and holds promise for future

The @oncbrothers.bsky.social are discussing the adjuvant CDK4/6 inhibitor landscape, Drs @laurahuppert.bsky.social and @neil-iyengarmd.bsky.social agree shared decision making with patients in key. #SABCS24

@aryaroy.bsky.social interviewing on behalf of @oncbrothers.bsky.social 🎙️ 🎬She did an amazing job!! 👏

Wow! Median PFS was 44.3 months for pts treated with IBRANCE in combination with HP and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with HP and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); p= 0.0074]. 44 month first-line PFS! @oncbrothers.bsky.social #SABCS

Fantastic event held yesterday by the @oncbrothers.bsky.social - truly thought provoking discussion with giants in the breast cancer space! Honored to be apart of it! @neil-iyengarmd.bsky.social @laurahuppert.bsky.so @drsgraff.bsky.social #sabcs2024 #signifymd

@oncbrothers.bsky.social #AdvancesInOncology is about to start! Excited for a great session on recent treatment algorithms @drsgraff.bsky.social @neil-iyengarmd.bsky.social @laurahuppert.bsky.social @drsarahsammons.bsky.social

Wonderful discussion by @drsgraff.bsky.social and Dr Giuseppe Curigilano on treatment of #Her2 #breastcancer @oncbrothers.bsky.social #bcsm #sabcs

Drs. @drsarahsammons.bsky.social and @drgattimays.bsky.social share pearls with @oncbrothers.bsky.social on managing early stage TNBC #SABCS24